Evidence map›Paper›PMID 40143173›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Puerarin Targets HIF-1α to Modulate Hypoxia-Related Sphingolipid Metabolism in Diabetic Hepatopathy via the SPTLC2/Ceramide Pathway.

Mangui Cai, Wenxi Lai, Huien Chen, Dongmin Cao, Boyan Zhang, Feng Wang, Minghua Xian, Shumei Wang

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Jiangtang Decoction for Type 2 Diabetes and NAFLD: Integrative AnalysisEndocrine, metabolic & immune disorders drug targets · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mangui CaiSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Wenxi LaiSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Huien ChenSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Dongmin CaoSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.ORCID 0000-0001-9218-5345
Boyan ZhangSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Feng WangSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Minghua XianSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.ORCID 0000-0002-6444-7595
Shumei WangSchool of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.ORCID 0000-0002-6538-8689

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515011147Guangdong Basic and Applied Basic Research Foundation 2024A1515012779National Major Scientific and Technological Special Project for "Significant New Drugs Develop-ment" 2017ZX09301077National Natural Science Foundation of China 81473413National Natural Science Foundation of China 81773884National Natural Science Foundation of China 82173972National Natural Science Foundation of China 82474083Training Program for Undergraduates of Guangdong Pharmaceutical University S202410573003
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ceramidediabetic hepatopathyHIF-1αmetabolic pathwaysPuerarin

Identifiers

PMID40143173
PMCPMC11945571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.